With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Last trade$40.70
Day change-$0.90 (-2.16%)
Day range$40.28 – $41.53
Volume12,213,869
Market cap$183.35B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NVO.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NVO.
Recent news
Company coverage with links to the original publishers.
Johnson & Johnson demonstrates strong revenue growth with consistent quarter-over-quarter increases, while Novo Nordisk struggles with largely flat revenue despite a notable spike in Q1 2026. JNJ's diverse portfolio of 28+ billion-dollar products contrasts with Novo Nordisk's challenges as competitors catch up in the GLP-1 weight loss market.
Novo Nordisk received European Commission approval for Frehemgo (denecimig), a next-generation bispecific antibody for hemophilia A prophylaxis. The company also presented positive Phase III data for CagriSema, showing 20.7-21.0% weight loss at 68 weeks versus 2.0% for placebo, with FDA decision expected in Q4 2026. However, Novo faces intensifying competition from Eli Lilly's obesity and diabetes drugs.
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
An analysis of two leading weight-loss drug manufacturers projects that $10,000 invested equally between Eli Lilly and Novo Nordisk could grow to approximately $11,230 by end of 2027. Eli Lilly is experiencing strong momentum with 39% revenue growth and upcoming retatrutide filing, while Novo Nordisk is bouncing back with oral Wegovy success and the promising CagriSema candidate. Both companies are positioned to benefit from the fast-growing obesity treatment market.
The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) and iShares Biotechnology ETF (IBB). PPH focuses on 26 large, established drugmakers with lower volatility, higher dividend yield (1.8%), and lower expense ratio (0.36%). IBB offers broader diversification with 243 holdings but higher volatility and minimal dividend yield (0.2%). The author recommends PPH for long-term investors seeking stability and income, particularly given the major pharmaceutical companies' acquisition activity in biotech.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 17, 2026
$0.5792
Aug 25, 2026
recurring
Mar 30, 2026
$1.2174
Apr 8, 2026
recurring
Aug 18, 2025
$0.5843
Aug 26, 2025
recurring
Mar 31, 2025
$1.1426
Apr 8, 2025
recurring
Aug 16, 2024
$0.5169
Aug 26, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.